NPM1-mut/FLT3-ITD-negative was included in the favorable group; the outcome of these patients harboring myelodysplasia-related mutations was worse than the outcome of the patients without myelodysplasia-related mutations (CR rates: 67% vs. 81%, respectively; PFS: 30% vs. 43%, respectively; 5-year OS: 32% vs. 42%, respectively) [38]. This evidence concerns the gene NPM1 and Myelodysplasia.